The Effectiveness of Pharmacist Interventions on Cardiovascular Risk: The Multicenter Randomized Controlled RxEACH Trial
- PMID: 27058907
- DOI: 10.1016/j.jacc.2016.03.528
The Effectiveness of Pharmacist Interventions on Cardiovascular Risk: The Multicenter Randomized Controlled RxEACH Trial
Abstract
Background: Despite the cardiovascular disease (CVD) risk associated with hypertension, diabetes, dyslipidemia, and smoking, these risk factors remain poorly identified and controlled.
Objectives: The study sought to evaluate the effectiveness of a community pharmacy-based case finding and intervention on cardiovascular risk.
Methods: The RxEACH (Alberta Vascular Risk Reduction Community Pharmacy Project) study was a randomized trial conducted in 56 community pharmacies. Participants were recruited by their pharmacist, who enrolled adults at high risk for CVD. Patients were randomized to usual care (usual pharmacist care with no specific intervention) or intervention, comprising a Medication Therapy Management review from their pharmacist and CVD risk assessment and education. Pharmacists prescribed medications and ordered laboratory tests as per their scope of practice to achieve treatment targets. Subjects received monthly follow-up visits for 3 months. The primary outcome was difference in change in estimated CVD risk between groups at 3 months. CVD risk was estimated using the greater of the Framingham, International, or United Kingdom Prospective Diabetes Study risk scores.
Results: We enrolled 723 patients (mean 62 years of age; 58% male, and 27% smokers). After adjusting for baseline values and center effect, there was a 21% difference in change in risk for CVD events (p < 0.001) between the intervention and usual care groups. The intervention group had greater improvements in low-density lipoprotein cholesterol (-0.2 mmol/l; p < 0.001), systolic blood pressure (-9.37 mm Hg; p < 0.001), glycosylated hemoglobin (-0.92%; p < 0.001), and smoking cessation (20.2%; p = 0.002).
Conclusions: The RxEACH study was the first large randomized trial of CVD risk reduction by community pharmacists, demonstrating a significant reduction in risk for CVD events. Engagement of community pharmacists with an expanded scope of practice could have significant public health implications. (The Alberta Vascular Risk Reduction Community Pharmacy Project: RxEACH [RxEACH]; NCT01979471).
Keywords: blood pressure; diabetes; dyslipidemia; smoking.
Copyright © 2016 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.
Comment in
-
Cardiovascular Risk Reduction and the Community Pharmacist.J Am Coll Cardiol. 2016 Jun 21;67(24):2855-7. doi: 10.1016/j.jacc.2016.04.018. J Am Coll Cardiol. 2016. PMID: 27311524 No abstract available.
Similar articles
-
Effectiveness of Pharmacist Interventions on Cardiovascular Risk in Patients With CKD: A Subgroup Analysis of the Randomized Controlled RxEACH Trial.Am J Kidney Dis. 2018 Jan;71(1):42-51. doi: 10.1053/j.ajkd.2017.07.012. Epub 2017 Sep 12. Am J Kidney Dis. 2018. PMID: 28912054 Clinical Trial.
-
The Effectiveness of Pharmacist Interventions on Cardiovascular Risk in Adult Patients with Type 2 Diabetes: The Multicentre Randomized Controlled RxEACH Trial.Can J Diabetes. 2017 Dec;41(6):580-586. doi: 10.1016/j.jcjd.2017.08.244. Epub 2017 Sep 28. Can J Diabetes. 2017. PMID: 28965748 Clinical Trial.
-
Diabetes and cardiovascular disease risk screening model in community pharmacies in a developing primary healthcare system: a feasibility study.BMJ Open. 2019 Nov 10;9(11):e031246. doi: 10.1136/bmjopen-2019-031246. BMJ Open. 2019. PMID: 31712336 Free PMC article.
-
Impact of pharmacist care in the management of cardiovascular disease risk factors: a systematic review and meta-analysis of randomized trials.Arch Intern Med. 2011 Sep 12;171(16):1441-53. doi: 10.1001/archinternmed.2011.399. Arch Intern Med. 2011. PMID: 21911628 Review.
-
Mobile phone-based interventions for improving adherence to medication prescribed for the primary prevention of cardiovascular disease in adults.Cochrane Database Syst Rev. 2018 Jun 22;6(6):CD012675. doi: 10.1002/14651858.CD012675.pub2. Cochrane Database Syst Rev. 2018. Update in: Cochrane Database Syst Rev. 2021 Mar 26;3:CD012675. doi: 10.1002/14651858.CD012675.pub3. PMID: 29932455 Free PMC article. Updated. Review.
Cited by
-
Community-Based Pharmacists' Perspectives on Prescribing Authority for the Minor Ailments and Contraception Service in British Columbia.Innov Pharm. 2024 Aug 21;15(3):10.24926/iip.v15i3.6230. doi: 10.24926/iip.v15i3.6230. eCollection 2024. Innov Pharm. 2024. PMID: 39483504 Free PMC article.
-
[Pilot programme for screening perimenopausal women for cardiovascular risk from community pharmacy: MENOVASC Project].Farm Comunitarios. 2023 Apr 14;15(3):17-24. doi: 10.33620/FC.2173-9218.(2023).17. eCollection 2023 Jul 15. Farm Comunitarios. 2023. PMID: 39157698 Free PMC article. Spanish.
-
Enhancing hypertension detection and control through a hypertension certification program for pharmacists: A cluster randomized trial (The RxPATH Study).Can Pharm J (Ott). 2024 May 31;157(4):190-199. doi: 10.1177/17151635241254089. eCollection 2024 Jul-Aug. Can Pharm J (Ott). 2024. PMID: 39092087 Free PMC article.
-
Navigating the challenges of clinical trial professionals in the healthcare sector.Front Med (Lausanne). 2024 Jun 3;11:1400585. doi: 10.3389/fmed.2024.1400585. eCollection 2024. Front Med (Lausanne). 2024. PMID: 38887672 Free PMC article. Review.
-
Community Pharmacy-Based Blood Pressure Screening in Newfoundland and Labrador, Canada for World Hypertension Day 2022: A Cross-Sectional Study.CJC Open. 2023 Dec 15;6(5):728-734. doi: 10.1016/j.cjco.2023.12.012. eCollection 2024 May. CJC Open. 2023. PMID: 38846443 Free PMC article.
Publication types
MeSH terms
Substances
Associated data
LinkOut - more resources
Full Text Sources
Other Literature Sources
